{"id":337071,"date":"2018-11-06T09:28:50","date_gmt":"2018-11-06T08:28:50","guid":{"rendered":"https:\/\/medizinonline.com\/niraparib-approved-with-individual-starting-doses\/"},"modified":"2018-11-06T09:28:50","modified_gmt":"2018-11-06T08:28:50","slug":"niraparib-approved-with-individual-starting-doses","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/en\/niraparib-approved-with-individual-starting-doses\/","title":{"rendered":"Niraparib approved with individual starting doses"},"content":{"rendered":"<p>In October 2018, the poly (ADP-ribose) polymerase (PARP) inhibitor niraparib (<sup>Zejula\u00ae<\/sup>) was approved for the maintenance treatment of relapsed ovarian cancer [1]. It can be used regardless of BRCA mutation status and received approval for the first time in Switzerland at a starting dose of 200 mg per day [1].<\/p>\n<p> <!--more--> <\/p>\n<p>Special report: maintenance therapy of relapsed ovarian cancer.<br \/>\n<strong>Niraparib approved with individual starting doses<\/strong><\/p>\n<h1 id=\"pdf-download\"><a href=\"https:\/\/assets.medizinonline.com\/sites\/default\/files\/sonderreport_eierstockkrebs_tesaro.pdf\" target=\"_blank\" rel=\"noopener\"><strong><u>&gt;&gt;&gt;  PDF Download<\/u><\/strong><\/a><\/h1>\n<p>&nbsp;<\/p>\n<p><img fetchpriority=\"high\" decoding=\"async\" class=\" size-full wp-image-11256\" alt=\"\" src=\"https:\/\/medizinonline.com\/wp-content\/uploads\/2018\/11\/10-12_oh6_sr22_tesaro.jpg\" style=\"height:778px; width:1100px\" width=\"1100\" height=\"778\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>In October 2018, the poly (ADP-ribose) polymerase (PARP) inhibitor niraparib (Zejula\u00ae) was approved for the maintenance treatment of relapsed ovarian cancer [1]. It can be used regardless of BRCA mutation&hellip;<\/p>\n","protected":false},"author":5,"featured_media":86087,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Special report: maintenance therapy of relapsed ovarian cancer.","footnotes":""},"category":[11400,11370,11548],"tags":[31269,31265,31258,31272],"powerkit_post_featured":[],"class_list":["post-337071","post","type-post","status-publish","format-standard","has-post-thumbnail","category-gynecology","category-oncology","category-rx-en","tag-niraparib-en","tag-ovarian-cancer-en-2","tag-special-report","tag-zejula-en","pmpro-has-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-06-17 03:56:55","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"en_US","wpml_translations":{"fr_FR":{"locale":"fr_FR","id":337077,"slug":"niraparib-approuve-avec-un-dosage-de-depart-personnalise","post_title":"Niraparib approuv\u00e9 avec un dosage de d\u00e9part personnalis\u00e9","href":"https:\/\/medizinonline.com\/fr\/niraparib-approuve-avec-un-dosage-de-depart-personnalise\/"},"it_IT":{"locale":"it_IT","id":337036,"slug":"niraparib-approvato-con-dose-iniziale-individuale","post_title":"Niraparib approvato con dose iniziale individuale","href":"https:\/\/medizinonline.com\/it\/niraparib-approvato-con-dose-iniziale-individuale\/"},"pt_PT":{"locale":"pt_PT","id":337058,"slug":"niraparib-aprovado-com-dose-inicial-individual","post_title":"Niraparib aprovado com dose inicial individual","href":"https:\/\/medizinonline.com\/pt-pt\/niraparib-aprovado-com-dose-inicial-individual\/"},"es_ES":{"locale":"es_ES","id":337068,"slug":"niraparib-aprobado-con-dosis-inicial-individual","post_title":"Niraparib aprobado con dosis inicial individual","href":"https:\/\/medizinonline.com\/es\/niraparib-aprobado-con-dosis-inicial-individual\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/337071","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/comments?post=337071"}],"version-history":[{"count":0,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/337071\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media\/86087"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media?parent=337071"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/category?post=337071"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/tags?post=337071"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/powerkit_post_featured?post=337071"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}